| Dr Roderic Joel Hartman, MD | |
|
1896 E Babbitt Lane, San Luis, AZ 85349-1669 | |
| (928) 722-6112 | |
| (928) 722-6113 |
| Full Name | Dr Roderic Joel Hartman |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 1896 E Babbitt Lane, San Luis, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962607317 | NPI | - | NPPES |
| 651170616 | Other | AZ | TAX ID |
| 907349 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | G87523 (California) | Secondary |
| 208000000X | Pediatrics | 21315 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Roderic Joel Hartman, MD Po Box 1669, 1896 E Babbitt Lane, San Luis, AZ 85349-1669 Ph: (928) 722-6112 | Dr Roderic Joel Hartman, MD 1896 E Babbitt Lane, San Luis, AZ 85349-1669 Ph: (928) 722-6112 |
News Archive
An early-phase clinical trial of an experimental vaccine that targets cancer stem cells in patients with recurrent glioblastoma multiforme, the most common and aggressive malignant brain tumor, has been launched by researchers at Cedars-Sinai's Department of Neurosurgery, Johnnie L. Cochran, Jr. Brain Tumor Center and Department of Neurology.
The Associated Press: "A new government study finds a 400 percent increase in the number of people admitted to treatment for abusing prescription pain medication. The increase in substance abuse among people ages 12 and older was recorded during the 10-year-period from 1998 to 2008. It spans every gender, race, ethnicity, education and employment level, and all regions of the country" (7/15).
New research from Baylor College of Medicine scientists shows that a combination of deep brain stimulation (DBS) and exercise has potential benefits for treating ataxia, a rare genetic neurodegenerative disease characterized by progressive irreversible problems with movement.
In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.
Success in the laboratory suggests that a new compound can point the way to preventing active tuberculosis in people infected with the latent form of the bacterium, says a team led by researchers at Weill Cornell Medical College in New York City.
› Verified 6 days ago
Sucharitha Gunasekera, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 815 E Juan Sanchez Blvd, San Luis, AZ 85349 Phone: 928-627-3822 Fax: 928-627-3989 | |
Victoria Lasala, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1896 E Babbitt Ln, San Luis, AZ 85349 Phone: 928-722-6112 Fax: 928-722-6113 | |
Jean M. Amon, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1896 E. Babbit Ln, Suite D, San Luis, AZ 85349 Phone: 928-722-6112 Fax: 928-722-6113 | |
Dr. Leonardo Rodriguez, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1896 E Babbitt Ln, San Luis, AZ 85349 Phone: 928-722-6112 Fax: 928-722-6113 | |
Daniel Anthony Calabrese, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1896 E. Babbit Lane, San Luis, AZ 85349 Phone: 928-722-6112 Fax: 928-722-6113 |